HOUSTON, Nov. 19, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biopharmaceutical company specializing in the
development of novel treatments for primary and metastatic cancers
of the brain and central nervous system, today announced its joint
sponsorship with WPD Pharmaceuticals for the 2020 Society of
NeuroOncology (SNO) Virtual Meeting held November 19-21, 2020.
CNS and WPD's joint sponsorship is on the Supporter' level,
which includes a booth in the virtual exhibit hall. Dr.
Patrick Wen, Director of Center for
Neuro-Oncology at Dana-Farber Cancer Institute and member of CNS
Pharmaceuticals' Science Advisory Board, will be participating in a
panel discussion on clinical trials during the plenary session on
Friday, November 20, as well as in
online poster presentations.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary
and metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
clinical trial with Berubicin in malignant brain tumors, which
Reata conducted in 2006. In this trial the overall response rate of
stable disease or better was 44%. This 44% disease control rate was
based on 11 patients (out of 25 evaluable patients) with stable
disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a
limited patient sample size and, while promising, are not a
guarantee that similar results will be achieved in subsequent
trials. By the end of 2020, CNS expects to commence a Phase 2
clinical trial of Berubicin for the treatment of GBM in the U.S.,
while a sub-licensee partner undertakes a Phase 2 trial in adults
and a first-ever Phase 1 trial in pediatric GBM patients in
Poland. Its second drug candidate,
WP1244, is a novel DNA binding agent that has shown in preclinical
studies that it is 500 times more potent than the chemotherapeutic
agent daunorubicin in inhibiting tumor cell proliferation.
For more information, please visit www.CNSPharma.com.
About WPD Pharmaceuticals
WPD is a biotechnology research and development company with a
focus on oncology and virology, namely research and development of
medicinal products involving biological compounds and small
molecules. WPD has licensed in certain countries 10 novel drug
candidates with 4 that are in clinical development stage. These
drug candidates were researched at medical institutions, and WPD
currently has ongoing collaborations with Wake
Forest University and leading hospitals and academic centers
in Poland.
WPD has entered into license agreements with Wake Forest University Health Sciences and
sublicense agreements with Moleculin Biotech, Inc. and CNS
Pharmaceuticals, Inc., respectively, each of which grant WPD an
exclusive, royalty-bearing sublicense to certain compounds for
about 30 countries, mostly in Europe. Such agreements provide WPD with
certain research, development, manufacturing and sales
rights and obligations, among other things.
For more information, please visit wpdpharmaceuticals.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-and-wpd-pharmaceuticals-to-contribute-sponsorship-to-2020-sno-virtual-meeting-301176680.html
SOURCE CNS Pharmaceuticals, Inc.